Abstract
Fuelled by the development of the serotonin 5-HT1B/1D receptor agonists, the triptans, the last 15 years has seen an explosion of interest in the treatment of acute migraine and cluster headache. Sumatriptan was the first of these agonists, and it launched a wave of therapeutic advances. These medicines are effective and safe. Triptans were developed as cranial vasoconstrictors to mimic the desirable effects of serotonin, while avoiding its side-effects. It has subsequently been shown that the triptans’major action is neuronal, with both peripheral and central trigeminal inhibitory effects, as well as actions in the thalamus and at central modulatory sites, such as the periaqueductal grey matter. Further refinements may be possible as the 5-HT1D and 5-HT1F receptor agonists are explored. Serotonin receptor pharmacology has contributed much to the better management of patients with primary headache disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adham N, Kao HT, Schechter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA (1993) Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90:408–412
Afridi S, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RSJ, Goadsby PJ (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62: 1270–1275
Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ (2001) Brainstem activation specific to migraine headache. Lancet 357:1016–1017
Bartsch T, Goadsby PJ (2002) Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 125:1496–1509
Bartsch T, Goadsby PJ (2003) Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 126:1801–1813
Bartsch T, Knight YE, Goadsby PJ (2004) Activation of 5-HT1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann Neurol 56:371–381
Benedetti F, Arduino C, Amanzio M (1999) Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci 19:3639–3648
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136–142
Bouchelet I, Cohen Z, Case B, Hamel E (1996) Differential expression of sumatriptansensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 50:219–223
Branchek T, Archa JE (1997) Recent advances in migraine therapy. In: Robertson DW (ed) Central nervous system disease. Academic Press, San Diego, pp 1–10
Burstein R, Yamamura H, Malick A, Strassman AM (1998) Chemical stimulation of the intracranialdura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 79:964–982
Burstein R, Cutrer MF, Yarnitsky D (2000a) The development of cutaneous allodynia during a migraine attack. Brain 123:1703–1709
Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000b) An association between migraine and cutaneous allodynia. Ann Neurol 47:614–624
Castro ME, Pascual J, Romon T, del Arco C, del Olmo E, Pazos A (1997) Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 36:535–542
Classey JD, Bartsch T, Goadsby PJ (2002) Immunohistochemical examination of 5HT1B, 5HT1D and 5HT1F receptor expression in rat trigeminal ganglion (TRG) and dorsal root ganglia (DRG) neurons. Cephalalgia 22:595–596
Cohen AS, Matharu MS, Kalisch R, Friston K, Goadsby PJ (2004) Functional MRI in SUNCT shows differential hypothalamic activation with increasing pain. Cephalalgia 24: 1098–1099
Cohen ML, Schenck K (1999) 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 290:935–939
Connor HE, Bertin L, Gillies S, Beattie DT, Ward P, The GR205171 Clinical Study Group (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia 18:392
Cumberbatch MJ, Hill RG, Hargreaves RJ (1997) Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 328:37–40
Cumberbatch MJ, Hill RG, Hargreaves RJ (1998) Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 18:659–664
Cutrer FM, Limmroth V, Waeber C, Yu X, Moskowitz MA (1997) New targets for antimigraine drug development. In: Goadsby PJ, Silberstein SD (eds) Headache. Butterworth-Heinemann, Philadelphia, pp 59–72
Data J, Britch K, Westergaard N, Weihnuller F, Harris S, Swarz H, Silberstein S, Goldstein J, Ryan R, Saper J, Londborg P, Winner P, Klapper J (1998) A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenopausal females. Headache 38:380
De Vries P, Villalon CM, Saxena PR (1999) Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 375: 61–74
Diener HC, The RPR100893 Study Group (2003) RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23:183–185
Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC (1991) Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 44:97–112
Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA (1992) Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48:187–203
Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, Maassen Van Den Brink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J (2004) Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 44: 414–425
Doenicke A, Siegel E, Hadoke M, Perrin VL (1987) Initial clinical study of AH25086B (5-HT1-like agonist) in the acute treatment of migraine. Cephalalgia 7:437–438
Doenicke A, Brand J, Perrin VL (1988) Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1:1309–1311
Durham PL, Russo AF (1999) Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 19:3423–3429
Durham PL, Sharma RV, Russo AF (1997) Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J Neurosci 17:9545–9553
Earl NL, McDonald SA, Lowy MT, 4991W93 Investigator Group (1999) Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. Cephalalgia 19:357
Ebersberger A, Schaible HG, Averbeck B, Richter F (2001) Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 49:7–13
Edvinsson L (1999) Experimental headache models in animals and man. Martin Dunitz, London
Feindel W, Penfield W, McNaughton F (1960) The tentorial nerves and localization of intracranial pain in man. Neurology 10:555–563
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633–658
Fleishaker JC, Pearson LK, Knuth DW, Gomez Mancilla B, Francom SF, McIntosh MJ, Freestone S, Azie NE (1999) Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F. Int J Clin Pharmacol Ther 37:487–492
Fugelli A, Moret C, Fillion G (1997) Autoradiographic localization of 5-HT1E and 5-HT1F binding sites in rat brain: effect of serotonergic lesioning. J Recept Signal Transduct Res 17:631–645
Goadsby PJ (2000) The pharmacology of headache. Prog Neurobiol 62:509–525
Goadsby PJ (2001) Migraine, aura and cortical spreading depression: why are we still talking about it? Ann Neurol 49:4–6
Goadsby PJ, Classey JD (2003) Evidence for 5-HT1B,5-HT1D and 5-HT1 Freceptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122:491–498
Goadsby PJ, Hoskin KL (1996) Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 67:355–359
Goadsby PJ, Hoskin KL (1997) The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 190:367–375
Goadsby PJ, Hoskin KL (1999) Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain 82:15–22
Goadsby PJ, Kaube H (2000) Animal models of headache. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The headaches. Lippincott Williams and Wilkins, Philadelphia, pp 195–202
Goadsby PJ, Knight YE (1997) Inhibition of trigeminal neurons after intravenous administration of naratriptan through an action at the serotonin (5HT1B/1D) receptors. Br J Pharmacol 122:918–922
Goadsby PJ, Zagami AS (1991) Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 114:1001–1011
Goadsby PJ, Hoskin KL, Knight YE (1997) Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain 73:23–28
Goadsby PJ, Akerman S, Storer RJ (2001) Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex. Ann Neurol 50:804–807
Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine—current understanding and treatment. N Engl J Med 346:257–270
Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acutemigraine: a crossover study. Cephalalgia 17:785–790
Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001) Selective serotonin 1F [5-HT(1F)] receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358:1230–1234
Gomez-Mancilla B, Cutler NR, Leibowitz MT, Spierings ELH, Klapper JA, Diamond S, Goldstein J, Smith T, Couch JR, Fleishaker J, Azie N, Blunt DE (2001) Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21:727–732
Harrison SD, Balawi SA, Feinmann C, Harris M (1997) Atypical facial pain: a double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan. Eur Neuropsychopharmacol 7:83–88
Hoskin KL, Kaube H, Goadsby PJ (1996) Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiology study. Brain 119:249–256
Hoskin KL, Zagami A, Goadsby PJ (1999) Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 194:579–588
Hoskin KL, Bulmer DCE, Lasalandra M, Jonkman A, Goadsby PJ (2001) Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. J Anat 197:29–35
Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET (1990) Serotonin and migraine. Ann NY Acad Sci 600:587–598
Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ (1997) Possible mechanism of c-fos expression in trigeminal nucleus caudalis following spreading depression. Pain 72: 407–415
Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ (1998) Comment on Ingvardsen et al., Pain 72 (1997) 407-415—reply to Moskowitz et al. Pain 76:266–267
Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME, Adham N, Zgombick JM, Cohen ML, Branchek TA, Phebus LA (1997) 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuro Report 8:2237–2240
Johnston BM, Saxena PR (1978) The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 63: 541–549
Kaube H, Hoskin KL, Goadsby PJ (1992) Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia 12:133–136
Kaube H, Hoskin KL, Goadsby PJ (1993a) Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 109:788–792
Kaube H, Hoskin KL, Goadsby PJ (1993b) Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33:541–550
Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ (1993c) Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res 629:95–102
Kimball RW, Friedman AP, Vallejo E (1960) Effect of serotonin in migraine patients. Neurology 10:107–111
Knight YE, Goadsby PJ (2001) The periaqueductal gray matter modulates trigeminovascular input: a role in migraine? Neuroscience 106:793–800
Knight YE, Bartsch T, Kaube H, Goadsby PJ (2002) P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22:1–6
Knight YE, Bartsch T, Goadsby PJ (2003) Trigeminal antinociception induced by bicuculline in the periaqueductal grey (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neurosci Lett 336:113–116
Lambert GA, Lowy AJ, Boers P, Angus-Leppan H, Zagami A (1992) The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res 597:321–330
Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS (2002) Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 953:181–188
Lance JW, Fine RD, Curran DA (1963) An evaluation of methysergide in the prevention of migraine and other vascular headache. Med J Aust 1:814–818
Lance JW, Anthony M, Hinterberger H (1967) The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 7:93–102
Levy D, Jakubowski M, Burstein R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 101:4274–4279
Lipton RB, Stewart WF, Cady R, Hall C, O’Quinn S, Kuhn T, Gutterman D (2000) Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40:783–791
Maneesi S, Akerman S, Lasalandra MP, Classey JD, Goadsby PJ (2004) Electron microscopic demonstration of pre-and postsynaptic 5-HT1D and 5-HT1F receptor immunoreactivity (IR) in the rat trigeminocervical complex (TCC) new therapeutic possibilities for the triptans. Cephalalgia 24:148
Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129–4136
Markowitz S, Saito K, Moskowitz MA (1988) Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8:83–91
Matharu MS, Goadsby PJ (2004) Cluster headache: a review with a focus on emerging therapies. Expert Rev Neurother 4:895–907
May A, Gijsman HJ, Wallnoefer A, Jones R, Diener HC, Ferrari MD (1996) Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67:375–378
May A, Bahra A, Buchel C, Frackowiak RSJ, Goadsby PJ (1998a) Hypothalamic activation in cluster headache attacks. Lancet 352:275–278
May A, Shepheard S, Wessing A, Hargreaves RJ, Goadsby PJ, Diener HC (1998b) Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain 121:1231–1237
May A, Bahra A, Buchel C, Turner R, Goadsby PJ (1999) Functional MRI in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing. Ann Neurol 46:791–793
McCall RB, Huff R, Chio CL, TenBrink R, Bergh CL, Ennis MD, Ghazal NB, Hoffman RL, Meisheri K, Higdon NR, Hall E (2002) Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT 1Dreceptor agonist PNU-142633. Cephalalgia 22:799–806
McNaughton FL (1966) The innervation of the intracranial blood vessels and the dural sinuses. In: Cobb S, Frantz AM, Penfield W, Riley HA (eds) The circulation of the brain and spinal cord. Hafner Publishing, New York, pp 178–200
Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C (1999) Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 369:271–277
Morgan JI, Curran T (1991) Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14:421–451
Moskowitz MA (1990) Basic mechanisms in vascular headache. Neurol Clin 8:801–815
Moskowitz MA, Cutrer FM (1993) Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 44:145–154
Moskowitz MA, Nozaki K, Kraig RP (1993) Neocortical spreading depression provokes the expression of C-fos protein-like immunoreactivity within the trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167–1177
Norman B, Panebianco D, Block GA (1998) A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia 18:407
Nozaki K, Boccalini P, Moskowitz MA (1992) Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 49:669–680
Pascual J, Arco Cd, Romon T, Olmo Cd, Pazos A (1996) [3H] Sumatriptan binding sites in human brain: regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 295:271–274
Penfield W (1932a) Intracerebral vascular nerves. AMA Arch Neurol Psychiatry 27:30–44
Penfield W (1932b) Operative treatment of migraine and observations on the mechanism of vascular pain. Trans Am Acad Ophthalmol Otolaryngol III:1–16
Penfield W (1934) A contribution to the mechanism of intracranial pain. Proc Assoc Res Nerv Mental Dis 15:399–415
Penfield W, McNaughton FL (1940) Dural headache and the innervation of the dura mater. AMA Arch Neurol Psychiatry 44:43–75
Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DLG, Calligaro DO, Kiefer AD, Branchek TA, Flaugh ME (1997) Characterization of LY334370 as a pharmacological tool to study 5HT1F receptors-binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61: 2117–2126
Potrebic S, Ahan AH, Skinner K, Fields HL, Basbaum AI (2003) Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 23:10988–10997
Pozo-Rosich P, Oshinsky M (2005) Effect of dihydroergotamine (DHE) on central sensitization of neurons in the trigeminal nucleus caudalis. Neurology 64:A151
Pregenzer JF, Alberts GL, Block JH, Slightom JL, Im WB (1997) Characterisation of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors. Neurosci Lett 235:117–120
Pregenzer JF, Alberts GL, Im WB, Slightom JL, Ennis MD, Hoffman RL, Ghazal NB, Ten-Brink RE (1999) Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Br J Pharmacol 127:468–472
Raskin NH, Hosobuchi Y, Lamb S (1987) Headache may arise from perturbation of brain. Headache 27:416–420
Ray BS, Wolff HG (1940) Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 41:813–856
Razzaque Z, Heald MA, Pickard JD, Maskell L, Beer MS, Hill RG, Longmore J (1999) Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B-and 5-HT1F-receptor activation. Br J Clin Pharmacol 47:75–82
Roon K, Diener HC, Ellis P, Hettiarachchi J, Poole P, Christiansen I, Ferrari MD, Olesen J (1997) CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia 17:245
Saxena PR, Cairo-Rawlins WI (1979) Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. Eur J Pharmacol 58:305–312
Saxena PR, De Boer MO (1991) Pharmacology of antimigraine drugs. J Neurol 238:S28–S35
Selby G, Lance JW (1960) Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 23:23–32
Shields KG, Goadsby PJ (2004) Naratriptan modulates trigeminovascular nociceptive transmission in the ventroposteromedial (VPM) thalamic nucleus of the rat. Cephalalgia 24:1098
Shields KG, Goadsby PJ (2005) Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 128:86–97
Shields KG, Kaube H, Goadsby PJ (2003) GABA receptors modulate trigeminovascular nociceptive transmission in the ventroposteromedial (VPM) thalamic nucleus of the rat. Cephalalgia 23:728
Steuer H, Jaworski A, Stoll D, Schlosshauer B (2004) In vitromodel of the outer blood-retina barrier. Brain Res Brain Res Protoc 13:26–36
Storer RJ, Goadsby PJ (1997) Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 120:2171–2177
Strassman AM, Raymond SA, Burstein R (1996) Sensitization ofmeningeal sensory neurons and the origin of headaches. Nature 384:560–563
Veloso F, Kumar K, Toth C (1998) Headache secondary to deep brain implantation. Headache 38:507–515
Waeber C, Moskowitz MA (1995) [3H]Sumatriptan labels both 5-HT1D and 5HT1F receptor bindings sites in the guinea pig brain: an autoradio graphic study. Naunyn Schmiedebergs Arch Pharmacol 352:263–275
Waeber C, Cutrer FM, Yu XJ, Moskowitz MA (1997) The selective 5HT1D receptor agonist U-109291 blocks dural plasma extravasation and c-fos expression in the trigeminal nucleus caudalis. Cephalalgia 17:401
Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL (1998) Human 5-HT1F receptor-stimulated [S-35]GTP gamma S binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol 352:117–124
Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658–660
Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 17:525–531
Wolff HG (1948) Headache and other head pain. Oxford University Press, New York
Zagami AS, Goadsby PJ (1991) Stimulation of the superior sagittal sinus increases metabolic activity in cat thalamus. In: Rose FC (ed) New advances in headache research: 2. Smith-Gordon, London, pp 169–171
Zagami AS, Lambert GA (1991) Craniovascular application of capsaicin activates nociceptive thalamic neurons in the cat. Neurosci Lett 121:187–190
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Goadsby, P.J. (2006). Serotonin Receptor Ligands: Treatments of Acute Migraine and Cluster Headache. In: Stein, C. (eds) Analgesia. Handbook of Experimental Pharmacology, vol 177. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33823-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-33823-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-33822-2
Online ISBN: 978-3-540-33823-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)